{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["TNO155"],["TNO155","nazartinib"]],"indication":"advanced solid tumors","name":"NCT03114319","nct_id":"NCT03114319","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03114319. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"TNO155 for oral administration","label":"TNO155","type":"EXPERIMENTAL"},{"description":"TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC","label":"TNO155 in combination with EGF816 (nazartinib)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-07-04","type":"ACTUAL"},"conditions":["Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)","KRAS G12-mutant NSCLC","Esophageal Squamous Cell Cancer (SCC)","Head/Neck SCC","Melanoma","Advanced Gastrointestinal Stromal Tumors (GIST)","Advanced NRAS/BRAFT wt Cutaneous Melanoma"],"enrollment":{"count":227,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"TNO155","otherNames":[],"type":"DRUG"},{"name":"TNO155 in combination with EGF816 (nazartinib)","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-09","lead_sponsor":"Novartis Pharmaceuticals","official_title":"An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-07-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants with adverse events and serious adverse events","timeFrame":"up to 5 years; at least once per treatment cycle"},{"measure":"Number of participants with dose limiting toxicities","timeFrame":"up to 28-day cycle"},{"measure":"Number of participants with dose interruptions and reductions","timeFrame":"Up to 5 years"},{"measure":"Dose intensity of study drugs","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2017-05-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03114319"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03114319"}